Clinical trials: immunohistochemistry staining method
- Drug or intervention immunohistochemistry staining method
- Funder type Industry (pharma, biotech, devices)
Cervical Cancers, Endometrial Cancer
A Study to Investigate the Prevalence of Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ and Characterize the Clinicopathologic Features of Gynecologic Cancers in Taiwan
Trastuzumab Deruxtecan (T-DXd) is a humanized anti-HER2 monoclonal antibody covalently linked to DXd, which is a topoisomerase 1 inhibitor.
- Conditions
- Cervical Cancers, Endometrial Cancer, Ovarian Cancer
- Trial name
- HERGYN (NCT06925113)
- Where
- 5 sites in Taiwan
- Volunteers
- 509 people
- Sponsor
- Daiichi Sankyo
Chronic Urticaria
Real-world Evaluation of the Effectiveness of Immunoglobulin-Histamine Complex, IHC (Histoglob) in Chronic Urticaria
This is a prospective, multicentre, non-interventional, observational, real-world evidence (RWE) study designed to evaluate the effectiveness and safety of Immunoglobulin/Histamine Complex (IHC) in patients with Chronic Urticaria…
- Trial name
- RUSH (NCT07680413)
- Testing
- Antihistaminics, H2 blockers, Leukotriene antagonists, Immunoglobulin/Histamine Complex (IHC) Injection
- Where
- 40 sites in India
- Volunteers
- 660 people
- Sponsor
- Bharat Serums and Vaccines Limited
Non-Small Cell Lung Cancer
PD-L1 Expression in Lung Cancer
This study will measure PD-L1 expression in metastatic NSCLC (primary tumour and metastatic lesions) using [99mTc]-NM-01 SPECT/CT and compare to PD-L1 percentage expression determined by immunohistochemistry (IHC).
- Trial name
- PELICAN (NCT04992715)
- Testing
- [99mTc]-NM01 SPECT/CT
- Where
- United Kingdom
- Volunteers
- 15 people
- Sponsor
- NanoMab Technology (UK) Limited
DiGeorge Syndrome, Hypoparathyroidism
Parathyroid and Thymus Transplantation in DiGeorge #931
This study has three primary purposes: to assess parathyroid function after parathyroid transplantation in infants with Complete DiGeorge syndrome; to assess immune function development after transplantation; and, to assess…
- Conditions
- DiGeorge Syndrome, Hypoparathyroidism, Complete DiGeorge Syndrome
- Trial name
- NCT00566488
- Testing
- Thymus/Parathyroid Transplantation
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Sumitomo Pharma Switzerland GmbH
Breast Cancer
Immunohistochemical (IHC) Scoring for Receptors Expression in Breast Tissues
The purpose of this study is the identification and classification of human tissues and cytology specimens and elements therein.
- Trial name
- NCT00978276
- Sponsor
- Applied Spectral Imaging Ltd.
Breast Cancer
Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast Cancer
The purpose of this study is to determine if margetuximab is effective in the treatment of certain patients with relapsed or refractory advanced breast cancer.
- Trial name
- NCT01828021
- Testing
- Margetuximab
- Where
- 6 sites in United States
- Volunteers
- 25 people
- Sponsor
- MacroGenics
Breast Cancer
18F-FLT-PET in Breast Cancer (MK-0000-139)
This study correlated changes from baseline in Ki-67, an immunohistochemical marker of cell proliferation, with changes from baseline in tumor uptake of 3'-deoxy-3'[18F]-fluorothymidine (18F-FLT) following the first cycle of…
- Trial name
- NCT01015131
- Testing
- 18F-FLT-PET/CT Imaging
- Volunteers
- 46 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer
A Study of Prevalence of HER3 Expression in Non-Small Cell Lung Cancer
There is currently a lack of published HER3 expression prevalence data among non-small cell lung cancer (NSCLC) patients. The estimation of HER3 expression prevalence in this population using archival tissue samples and the…
- Trial name
- NCT05769764
- Testing
- Archival tissue specimen and immunohistochemistry staining
- Where
- 2 sites in United States
- Volunteers
- 225 people
- Sponsor
- Daiichi Sankyo
Cancer
Phase I Study of Triciribine Phosphate Monohydrate (TCN-PM, VD-0002) in Adult Subjects With Metastatic Cancer
Phase I dose escalation study of Triciribine Phosphate Monohydrate (TCN-PM) in patients with metastatic cancer whose tumors must be shown to be p-Akt positive.
- Trial name
- NCT00363454
- Testing
- Triciribine Phosphate Monohydrate
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Prescient Therapeutics, Ltd.
Membranous Nephropathy - PLA2R Induced, Kidney Diseases-except Membranous Nephropathy
Clinical Trial of PLA2R-IgG4 Detection Kit (Time-resolved Fluorescence Immunoassay)
The goal of this observational clinical trial is to compare assessment reagents with clinical diagnostic criteria in patients with membranous nephropathy.
- Trial name
- NCT05861869
- Where
- China
- Volunteers
- 450 people
- Sponsor
- Zhejiang Biostar Biotechnology Co.
Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell
A Study to Assess Programmed Death Ligand-1 (PD-L1) Expression in Cytological Versus Histological Lung Cancer Specimens
The primary purpose of this non-interventional, multinational study is to assess the feasibility of assessing PD-L1 protein expression on cytological samples as a surrogate for histological samples obtained from participants with…
- Trial name
- NCT03092739
- Testing
- PD-L1 Immunocytochemistry (ICC), PD-L1 Immunohistochemistry (IHC)
- Where
- 8 sites in Czechia, Germany and 4 more
- Volunteers
- 184 people
- Sponsor
- Hoffmann-La Roche
Solid Tumour
CIVO Intratumoural Microdosing of Anti-Cancer Therapies in Australia
This is a multi-center, open-label Phase 0 Master Protocol in Australia designed to study the localized pharmacodynamics (PD) of anti-cancer therapies within the tumour microenvironment (TME) when administered intratumourally in…
- Trial name
- NCT04891718
- Testing
- MVC-101, Nivolumab, MVC-101 + Nivolumab
- Where
- 3 sites in Australia
- Sponsor
- Presage Biosciences
Non-Small Cell Lung Cancer
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer
The primary objective of this trial is to evaluate the efficacy of trastuzumab deruxtecan in HER2-overexpressing and/or HER2-mutated advanced NSCLC participants.
- Trial name
- DESTINY-Lung01 (NCT03505710)
- Testing
- Trastuzumab deruxtecan
- Where
- 21 sites in United States, France and 3 more
- Volunteers
- 181 people
- Sponsor
- Daiichi Sankyo
Oral Neoplasm
Early Prediction of Oral Cancer by S100A7 Immunohistochemistry Signature-based Assessment
The purpose of this observational study is to evaluate the utility of the S100A7 immunohistochemistry signature-based assessment - STRATICYTE - in determining the risk of progression to cancer of clinically suspicious oral…
- Trial name
- NCT04622462
- Testing
- Standard of Care Histopathology, STRATICYTE Assessment
- Where
- 3 sites in Canada
- Volunteers
- 500 people
- Sponsor
- Proteocyte Diagnostics Inc.
Breast Cancer, Renal Cell Carcinoma
Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma
MARIO-3 is a Phase 2 multi-arm combination cohort study designed to evaluate IPI-549, Infinity Pharmaceutical's first-in-class, oral immuno-oncology product candidate targeting immune-suppressive tumor-associated myeloid cells…
- Trial name
- MARIO-3 (NCT03961698)
- Testing
- IPI-549 (eganelisib), Atezolizumab, nab-paclitaxel
- Where
- 24 sites in United States
- Volunteers
- 91 people
- Sponsor
- Infinity Pharmaceuticals, Inc.
Colorectal Cancer, Metastases
Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer
The purpose of this study is to determine that panitumumab will have clinically meaningful anti-tumor activity in patients with metastatic colorectal cancer who have developed progressive disease or relapsed while on or after…
- Trial name
- NCT00089635
- Testing
- Panitumumab
- Volunteers
- 203 people
- Sponsor
- Amgen
Lymphoma
A Study of Chinese Adults With Lymphoma
The main aim of this study is to improve methods of clinical testing and therapy for lymphoma participants. This study will involve collecting information about participants from past medical records.
- Trial name
- CREDIT (NCT05288491)
- Where
- 19 sites in China
- Volunteers
- 934 people
- Sponsor
- Takeda
Mouth Diseases
Evaluation of Oral Potentially Malignant Disorders (OPMDs) with STRATICYTE™
The purpose of this study is to validate the ability of the STRATICYTE™ predictive model to predict the transformation of oral potentially malignant disorders (OPMDs) to oral squamous cell carcinoma (OSCC) in a retrospective…
- Trial name
- NCT05853783
- Testing
- STRATICYTE™ Test
- Where
- 5 sites in United States
- Volunteers
- 180 people
- Sponsor
- Proteocyte Diagnostics Inc.
Metastatic Breast Cancer
Real-World Treatment Patterns and Outcomes in HER2-Altered Metastatic Breast Cancer Patients in the United States
This study aims to address the following key objectives in patients with HER2-altered mBC: Primary objectives Estimate the prevalence of human epidermal growth factor receptor 2 positive (HER2+), human epidermal growth factor…
- Trial name
- NCT07342309
- Where
- United States
- Volunteers
- 7,933 people
- Sponsor
- Boehringer Ingelheim
Breast Cancer
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
This study will evaluate the safety and efficacy of trastuzumab deruxtecan (T-DXd) in participants with human epidermal growth factor receptor 2 (HER2)-low or HER2 immunohistochemistry (IHC) 0 (who are both hormone receptor…
- Trial name
- NCT05950945
- Testing
- Trastuzumab Deruxtecan
- Where
- 88 sites in United States, Australia and 8 more
- Volunteers
- 250 people
- Sponsor
- Daiichi Sankyo